FigureAsia 35 Under 35 · Healthcare
Abigail Copiaco
Age 29 · Home-based autism assessment and assistive technology · Dubai, United Arab Emirates
Principal investigator of a 2025 Dubai-funded programme combining assistive sensing and artificial intelligence for home-based autism support.
- Approximate age at 31 December 2025
- 29
- Field
- Healthcare
- Country or region
- Dubai, United Arab Emirates
- FigureAsia U35 Assessment
- 82.6 / 100
Profile
Career and documented record
Abigail Copiaco is building autism technology around a setting where clinically relevant behaviour actually occurs: the home. In 2025, a Dubai research initiative awarded approximately US$322,668 to her programme for AI-powered assistive technology supporting home-based assessment and management. She is the named principal investigator, giving the work clear individual accountability.
The team's 2025 preprints explored models using public datasets and proposed system architectures for progressive, home-based observation. The approach could reduce travel burden and give clinicians a longer view than a short appointment. It also creates serious obligations around consent, family surveillance, bias, neurodiversity and the distinction between support and diagnosis.
No public clinical-validation cohort, diagnostic authorization or patient-outcome study has yet established the system's performance. Public-data model results cannot be treated as evidence that the tool works safely in homes. Copiaco's inclusion recognizes the funded programme, principal-investigator role and the relevance of designing for family context in the Gulf and wider Asian diaspora.
FigureAsia selection
Why Abigail Copiaco is on the list
FigureAsia selected Copiaco because she has framed a meaningful access problem and secured the resources to test it under independent academic leadership. Her work brings Filipino expertise into West Asia's research ecosystem and addresses families who may struggle to reach specialist services. The score is intentionally constrained by preprint maturity and the absence of clinical validation.
Verified work
The 2025–26 record
Principal milestone
Approximately US$322,668 grant launched in 2025
Evidence record
Named principal investigator
Scale or implementation
Two 2025 preprints describing the technical programme
Field context
The work in its field
Within home-based autism assessment and assistive technology, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
82.6out of 100
Substantive 2025–2026 contribution
20 / 20
The score reflects completed 2025–26 work in home-based autism assessment and assistive technology, assessed at the documented maturity of funded research programme and preprints.
Verified impact
9 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
10 / 10
The work creates or materially advances a distinctive capability within home-based autism assessment and assistive technology rather than relying on title or institutional association.
Field and industry influence
7 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
9 / 10
Named authorship and the documented role of Assistant Professor and Principal Investigator establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Filipino engineer and researcher based in the United Arab Emirates.
Clinical and scientific validity
4.9 / 7
Clinical and scientific validity is calibrated to funded research programme and preprints, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
5.6 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
3.6 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
4.5 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.